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The very large economic and social burdens of fracture-related complications make rapid fracture healing a
major public health goal. The role of parathyroid hormone (PTH) in treating osteoporosis is generally accepted,
but the effect of PTH on fracture healing is controversial. This meta-analysis was designed to investigate the
efficacy and safety of PTH in fracture healing. The EMBASE, PubMed, and Cochrane Library databases were
systematically searched from the inception dates to April 26, 2018. The primary randomized clinical trials
comparing PTH treatment for fracture healing with placebo or no treatment were identified. We did not gain
additional information by contacting the authors of the primary studies. Two reviewers independently
extracted the data and evaluated study quality. This meta-analysis was executed to determine the odds ratio,
mean difference, standardized mean difference, and 95% confidence intervals with random-effects models. In
total, 8 randomized trials including 524 patients met the inclusion criteria. There were significant differences in
fracture healing time, pain relief and function improvement. There were no significant differences in the
fracture healing rate or adverse events, including light-headedness, hypercalcemia, nausea, sweating and
headache, except for slight bruising at the injection site. We determined that the effectiveness and safety of PTH
in fracture healing is reasonably well established and credible.
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’ INTRODUCTION
It is estimated that there are 16 million cases of fractures
in the United States every year. Despite most bone having
excellent regenerative ability during fracture healing, appro-
ximately 5% to 10% of fractures have complications, such
as delayed healing or nonunion (1-3). Delayed healing and
nonunion are defined as fractures that have not healed for
6 and 9 months, respectively (4,5). The complications result
in extended treatment time, reduced quality of living and
potential additional remedial surgery, which give the patients
a heavy burden and have serious societal implications (1,6).
Fracture repair is an intricate process regulated by numerous
genes and is affected by chemokines, cytokines, growth
factors and other molecules (7-9). To promote bone regenera-
tion and prevent complications, an in-depth understanding of
the fracture healing process and the adoption of suitable
interventions are essential.
Parathyroid hormone (PTH) plays a vital role in bone regen-
eration by stimulating the differentiation and proliferation of
osteoblasts and osteoclasts (10,11). Osteoporosis has been
treated with intact PTH (1-84) and teriparatide, which is
an N-terminal fragment (1-34) of PTH (12). Currently,
teriparatide is the only anabolic bone therapeutic medicine
to treat osteoporosis approved by the Food and Drug
Administration (FDA) (13-16). In patients with high frac-
ture risk, PTH can improve bone quality and prevent
fractures (17).
As described previously, PTH treatment could increase
bone formation biomarkers higher than it increases bone
resorption biomarkers (18,19). Some animal studies have
demonstrated that daily application of PTH (1-34) could
increase bone mineral density to accelerate fracture healing
and persistently affect the remodeling callus during fracture
healing (20,21). Furthermore, studies have shown that PTH
could improve fracture healing at different skeletal sites of
patients (22-24). However, we found that recent studies in
the literature were inconsistent regarding the effects of PTH
treatment on fracture healing (25,26).
Therefore, a meta-analysis on randomized controlled trials
(RCTs) was performed to demonstrate whether PTH can
promote fracture healing by comparing PTH treatment to a
placebo treatment or no treatment in patients with fracture.
’ METHODS
This meta-analysis was conducted based on the Cochrane
Handbook for Systematic Reviews of Interventions (27)
and presented in compliance with Preferred ReportingDOI: 10.6061/clinics/2019/e800
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Items for Systematic Reviews and Meta-analyses guide-
lines (PRISMA) (28).
Search strategy
The EMBASE, PubMed, and Cochrane Library databases
were systematically searched from the inception dates to
April 26, 2018. The keywords and Medical Subject Headings
(MeSH) were ‘‘Parathyroid Hormone’’, ‘‘Hormone, Para-
thyroid’’, ‘‘Parathormone’’, ‘‘Parathyrin’’, ‘‘Parathyroid Hor-
mone Peptide (1-34)’’, ‘‘PTH (1-34)’’, ‘‘Parathyroid Hormone
(1-34)’’, ‘‘Teriparatide’’, ‘‘hPTH (1-34)’’, ‘‘Human Parathyroid
Hormone (1-34)’’, ‘‘Parathar’’, ‘‘Teriparatide Acetate’’, ‘‘For-
teo’’, ‘‘Parathyroid Hormone (1-84)’’ and ‘‘PTH (1-84)’’ in
combination with ‘‘Fracture Healing’’, ‘‘Healing, Fracture’’,
‘‘Healings, Fracture’’ and ‘‘Fracture Healings’’. We did not
restrict the language. The detailed search strategy is reported
in the supplement. We identified original RCTs and did not
obtain additional information by contacting authors of the
primary studies.
Inclusion criteria
Studies were included if they met the following criteria:
(A) participants, aged 21 to 94 years old, were patients with
fractures and treated by PTH; (B) RCTs comparing the PTH
intervention with a placebo or no treatment; (C) teriparatide
was subcutaneously injected at 20 mg per day, or PTH (1-84)
was administered at 100 mg per day; and (D) trials provided
the relevant data.
Studies were excluded if they met the following criteria:
(A) the patients had been using PTH, unless they had
experienced a wash-out period; (B) there were contraindica-
tions to related drugs at any time; (C) any other antiosteo-
porotic drug had been taken in either the experimental group
or comparison group; (D) liver enzymes were more than
twice the upper limit or serum calcium was higher than the
reference level; (E) patients had rheumatoid arthritis, patho-
logic fractures, history of tumor or chemotherapy, metabolic
bone disease, chronic renal failure, or any disease affecting
bone metabolism; (F) the studies were published as abstracts,
reviews or letters; or (G) the articles were not available or the
data had already been published.
Risk-of-bias assessments
According to the Cochrane risk-of-bias criteria (27), 2
researchers (HH, YL) independently evaluated the metho-
dological quality of the selected RCTs. Every quality item
was classified into unclear risk, low risk, or high risk. Any
disagreements about a trial were resolved through discus-
sion or consultation with an expert. Seven items were used to
assess bias, as shown in Figure 2. Other bias was defined as
trials with dissimilar baseline characteristics between groups
or with sponsorship coming from drug companies.
Data extraction
The following information from each study was extracted
independently by two researchers (HH, TS): authors,
publication year, participant characteristics, number of cases,
type of fracture, duration of trials, explicit treatment, drug
dose, fracture healing-related data and adverse events. Any
disagreements were resolved through discussion. We only
extracted the relevant information and data from the original
articles when more than 2 groups were compared in the
study.
The primary endpoints were the fracture healing rate and
time. When three of four fracture cortices were connected by
the bone bridge shown on either lateral or anteroposterior
radiographs, the fracture was considered healed (29-35).
A visual analog scale (VAS) (31,34,36,37) and the Patient-Rated
Wrist Evaluation (PRWE) were common methods for esti-
mating degree of pain (33). Kinematic mobility could quantify
functional outcomes using the PRWE (33), ‘‘Disabilities of the
Arm, Shoulder, and Hand’’ scoring (DASH) (37), Johanson
Hip Rating Questionnaire (JHRQ) (30), or Timed ‘‘Up and Go’’
test (TUG) (31). Because adverse events were reported by
inconsistent methods (29,32,33,36,37), we could not pool the
relevant data and only describe them in Table 7.
Statistical analysis
Our meta-analysis was conducted in Revman version 5.3
from the Cochrane Collaboration. We calculated the odds ratio
(OR) and 95% confidence intervals (CIs) using the Mantel-
Haenszel statistical method for dichotomous outcomes, while
we determined mean difference (MD) or standard mean
difference (SMD) and 95% CIs using the inverse variance
statistical method for continuous outcomes. The analyses
were 2-tailed, and the data pooled with a random-effects
model. po0.05 was considered statistically significant. Statis-
tical heterogeneity in the summary data was assessed with I2
statistics and p-values (I2450% or p-valueo0.10 was con-
sidered to indicate significant heterogeneity) (38,39). Sensitiv-
ity analyses were fulfilled by excluding the trials one by one.
We performed subgroup analyses to appraise whether clinical
characteristics could alter the results, to evaluate the statistical
significance between the subgroups, and to estimate the
publication bias with funnel plots.
Grading of evidence quality
Regarding risk of bias, inconsistency, indirectness, impre-
cision, and publication bias, the quality of evidence was
independently assessed by two authors (HH, YL) based on
the Grading of Recommendations Assessment, Develop-
ment, and Evaluation (GRADE) (40) methodology. The
estimated results were classified as very low, low, moderate,
or high. We constructed a summary table using the GRADE
Profiler (version 3.6).
’ RESULTS
Literature search and characteristics
From the recently published studies, 121 potentially eligible
RCTs were screened by titles and abstracts. There were 26
records read in full. Eventually, 8 records were in conformity
with the inclusion criteria. A manual search of the reference
lists within these studies did not reveal additional eligible
studies. The process of screening the studies is illustrated in
Figure 1.
Ultimately, in the meta-analysis, there were 524 partici-
pants from 8 RCTs, of which 79.6% were women and 20.4%
were men. The mean age was 73.0 years old. For the fracture
type, two trials had upper limb fractures (including distal
radial fractures and proximal humeral fractures), five
trials had lower limb fractures (including lower-extremity
stress fracture, femoral neck fracture, trochanteric fractured
neck of femur, osteoporotic intertrochanteric fractures, and
hip fractures), and one trial had pelvic fracture. The general
characteristics of the included studies are presented in
Table 1.
2
The effect of PTH in fracture healing
Hong H et al.
CLINICS 2019;74:e800
The experimental groups received once-daily subcuta-
neous treatment with 20 mg of teriparatide or 100 mg of PTH
(1-84). The anabolic effect of 20 mg teriparatide is equivalent
to 100 mg PTH (1-84) because of the differences in pharma-
cokinetics (41). The control group received a placebo, no
treatment, or other drugs. The duration of PTH treatment
ranged from 4 weeks to 24 months. The study by Aspenberg
et al. (33) included two experimental groups, taking 20 mg or
40 mg teriparatide. In the study by Huang et al. (34), the two
experimental groups could take either 20 mg teriparatide or
20 mg teriparatide plus 70 mg alendronate. Additionally, the
study by Kanakaris et al. (30) had two control groups that
took either vitamin D and calcium or vitamin D and calcium
plus 70 mg alendronate. We excluded those ineligible groups.
The detailed characteristics are shown in Table 2.
Risk-of-bias assessments
Methodological quality is shown in Figure 2. The inci-
dence of the follow-up loss in patients was appraised,
but only three trials had reported follow-up rates, which
were all lower than 20%.
Radiographic assessment of fracture healing
Three trials (251 patients) compared PTH treatment with
either a placebo or no treatment for the time until
radiological fracture healing (31,33,34). The MD method
was adopted. As shown in Figure 3, there was a statistically
significant difference in fracture healing time (MD -3.05, 95%
CI -5.96 to -0.14, p=0.04; I2 of heterogeneity 97%, p-value of
heterogeneity o0.00001). A sensitivity analysis showed that
the heterogeneity was significantly lower after the trial by
Peichl et al. (31) was excluded (Table 3).
Four trials (256 patients) compared PTH treatment with
either a placebo or no treatment regarding the rate of radio-
logical fracture healing (29-32). The OR method was adopted.
The results are shown in Figure 4. There was no statistically
significant difference in the fracture healing rate (OR 7.84, 95%
CI 0.47 to 130.27, p=0.15; I2 of heterogeneity 85%, p-value of
Table 1 - Characteristics of the included studies.
Study ID No. of patients Age/years Sex Type of fracture
Mean SD Male Female
Almirol et al., 2016 (32) 14 31.4 4.4 0 14 Lower-extremity stress fracture
Aspenberg et al., 2010 (33) 102 61.4 8.6 0 102 Distal radius fracture
Bhandari et al., 2016 (29) 159 70 10.5 42 117 Femoral neck fracture
Chesser et al., 2016 (36) 29 79.6 8.94 19 10 Trochanteric fractured neck of femur
Huang et al., 2016 (34) 189 81.2 8.5 61 128 Osteoporotic intertrochanteric fractures
Johansson et al., 2016 (37) 40 68 8.6 0 40 Proximal humeral fracture
Kanakaris et al., 2015 (30) 30 75 8.89 6 24 Hip fractures (low energy)
Peichl et al., 2011 (31) 65 82.8 4.1 0 65 Pelvic fracture
SD, standard deviation.
Figure 1 - Flow diagram of the study selection process.
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heterogeneity =0.0002). In a sensitivity analysis, the hetero-
geneity was significantly lower after the trial by Peichl et al.
(31) was excluded (Table 4).
Fracture pain degree
Five trials (320 patients) compared PTH treatment with
either a placebo or no treatment on the degree of fracture
pain by VAS or PRWE scores (31,33,34,36,37). Pain and
numbness were evaluated by VAS scores in patients with
trauma (31,34,36,37), while pain and function were evaluated
by PRWE scores in patients with distal radius fractures (33).
Due to the different scoring criteria, the SMD method was
adopted. The results are shown in Figure 5. There was a
statistically significant difference in fracture pain degree (SMD
-1.42, 95% CI -2.55 to -0.29, p=0.01; I2 of heterogeneity 94%,
P value of heterogeneity o0.00001). Considering the signifi-
cant heterogeneity, we did a subgroup analysis on the basis of
the distinct scoring methods. In the VAS score subgroup, there
was still significant heterogeneity (I2 of heterogeneity 94%,
p-value of heterogeneity o0.00001). We further performed a
sensitivity analysis in the VAS score subgroup and found thatTa
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Figure 2 - Risk-of-bias summary.
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Table 3 - Sensitivity analyses based on various exclusion criteria for fracture healing time.
Excluded trial No. of
trials
No. of
patients
Experimental
group
Control
group
MD (95% CI) p-value for
MD
I2,% p-value for
heterogeneity
Aspenberg et al., 2010 (33) 2 (31,34) 195 68 127 -3.73 [-8.53, 1.07] 0.13 99 o0.00001
Huang et al., 2016 (34) 2 (31,33) 121 50 71 -3.95 [-8.36, 0.46] 0.08 97 o0.00001
Peichl et al., 2011 (31) 2 (33,34) 186 76 110 -1.38 [-1.82, -0.94] o0.00001 0 0.48
MD, mean difference.
Table 4 - Sensitivity analyses based on various exclusion criteria for fracture healing rate.
Excluded trial No. of trials No. of
patients
Experimental
group
Control
group
OR (95% CI) p-value
for OR
I2, % p-value for
heterogeneity
Almirol et al., 2016 (32) 3 (29-31) 243 108 135 10.94 [0.19, 639.47] 0.25 90 o0.0001
Bhandari et al., 2016 (29) 3 (30-32) 97 36 61 19.60 [1.00, 385.14] 0.05 68 0.04
Kanakaris et al., 2015 (30) 3 (29,31,32) 237 105 132 9.21 [0.23, 366.63] 0.24 89 o0.0001
Peichl et al., 2011 (31) 3 (29,30,32) 191 93 98 1.14 [0.56, 2.31] 0.72 2 0.36
OR, odds ratio.
Figure 3 - Forest plot for radiological fracture healing time.
Figure 4 - Forest plot for the radiological fracture healing rate.
Figure 5 - Forest plot for degree of fracture pain.
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the heterogeneity was significantly lower after the trial by
Peichl et al. (31) was excluded (Table 5).
Functional outcome
Four trials (178 patients) compared PTH treatment with
either a placebo or no treatment on functional outcomes
(30,31,33,37). The functional outcome was assessed with
the TUG test or the self-administered PRWE questionnaire,
DASH score or JHRQ (30,31,33,37). Due to the different
methods, the SMD method was appropriate. The results are
shown in Figure 6. The patients with PTH treatment were
significantly superior to those with a placebo or no treatment
in functional outcome (SMD -1.28, 95% CI -2.33 to -0.24,
p=0.02; I2 of heterogeneity 88%, p-value of heterogeneity
o0.00001). In view of the result that there was significant
heterogeneity (I2=88%), we performed a subgroup analysis
based on the duration of treatment. One group had the
treatment time being equal to 4 weeks (SMD -0.42, 95% CI
-0.97 to 0.13, p=0.13; I2 of heterogeneity 7%, p of hetero-
geneity =0.30) and the other group included the treatment
time exceeding 4 weeks (SMD -2.17, 95% CI -2.89 to -1.45,
po0.00001; I2 of heterogeneity 57%, p of heterogeneity =0.13).
The sensitivity analysis for the functional outcomes showed
that the heterogeneity was not significantly lower after
any study was excluded (Table 6). Importantly, in this meta-
analysis, the functional outcomes were better when the
treatment times were longer than 4 weeks.
Adverse events
The trial by Peichl et al. declared that no deaths or adverse
events were recorded (31). The trial by Huang et al. and
Kanakaris et al. did not mention the relevant statistics about
adverse events (30,34). Five trials reported adverse events
with inconsistent methods (29,32,33,36,37). Therefore, we
could not pool the relevant data, but describe them in
Table 7. In comparing the PTH treatment group with a
control group, there was no significant difference in light-
headedness, hypercalcemia, nausea, sweating, and headache,
except for slight bruising at the injection site.
Publication Bias and GRADE Profile Evidence
For this meta-analysis, there was no evidence showing
obvious publication bias by examining the symmetry of the
Figure 6 - Forest plot for fracture functional outcome.
Table 5 - Sensitivity analyses based on various exclusion criteria for the subgroup of fracture pain degree by VAS scores.
Excluded trial No. of trials No. of
patients
Experimental
group
Control
group
SMD (95% CI) p-value
for SMD
I2,% p-value for
heterogeneity
Chesser et al., 2016 (36) 3 (31,34,37) 234 87 147 -1.40 [-3.03, 0.22] 0.09 96 o0.00001
Huang et al., 2016 (34) 3 (31,36,37) 133 55 78 -1.35 [-3.33, 0.63] 0.18 96 o0.00001
Johansson et al., 2016 (37) 3 (31,34,36) 224 83 141 -1.48 [-3.16, 0.20] 0.09 95 o0.00001
Peichl et al., 2011 (31) 3 (34,36,37) 198 81 117 -0.49 [-0.78, -0.20] 0.001 0 0.51
SMD, standardized mean difference.
Table 6 - Sensitivity analyses based on various exclusion criteria for functional outcomes.
Excluded trial No. of trials No. of
patients
Experimental
group
Control
group
SMD (95% CI) p-value
for SMD
I2,% p-value for
heterogeneity
Johansson et al., 2016 (37) 3 (30,31,33) 139 58 81 -1.51 [-2.81, -0.20] 0.02 89 o0.0001
Kanakaris et al., 2015 (30) 3 (31,33,37) 159 68 91 -1.66 [-2.74, -0.59] 0.002 88 0.0003
Aspenberg et al., 2010 (33) 3 (30,31,37) 123 49 74 -0.87 [-1.89, 0.16] 0.10 84 0.002
Peichl et al., 2011 (31) 3 (30,33,37) 113 56 57 -1.09 [-2.55, 0.38] 0.15 91 o0.0001
SMD, standardized mean difference.
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funnel plots (Figure 7), but a funnel shape reference line
could not be provided by the software due to the small
number of studies. GRADE evidence profiles are shown
in Table 8. There were no blind methods in the trials by
Huang et al. and Johansson et al., no random processing
in the trial by Huang et al., and inconsistent results in the
Table 7 - Adverse effects.
Study ID Adverse event description No. of events in
experimental group (%)
No. of events in control
group (%)
p-value
Almirol et al., 2016 (32) Slight bruising at the injection site 6 (100%) 0 (0%) 0.010
Pea-sized bump below the site of fracture 1 (16.7%) 0 (0%) 0.410
Light-headedness 0 (0%) 1 (14.3%) 0.520
Aspenberg et al., 2010 (33) Serious adverse events 0 (0%) 3 (8.8%) 0.046
Hypercalcemia 0 (0%) 1 (2.9%) 0.490
Nausea 3 (8.8%) 0 (0%) 0.279
A new distal radius fracture 0 (0%) 1 (2.9%) 0.490
Bhandari et al., 2016 (29) Patients with 4 1 adverse events 35 (45%) 40 (49%) 0.634
Patients with4 1 adverse events possibly related to
study drug
5 (6%) 5 (6%) 1.000
Patients with 4 1 serious adverse events 3 (4%) 7 (9%) 0.329
Chesser et al., 2016 (36) None of the serious adverse effects were related to
the study intervention
8 (53%) 7 (50%) 0.860
Huang et al., 2016 (34) Not mentioned - - -
Johansson et al., 2016 (37) Nausea 3 (15.8%) 0(0%) 0.160
Episodes of sweating 2 (10.5%) 0(0%) 0.260
Slight headache 1 (5.3%) 0(0%) 0.470
Kanakaris et al., 2015 (30) Not mentioned - - -
Peichl et al., 2011 (31) No adverse events or deaths were recorded - - -
Figure 7 - Publication bias summary.
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trial by Bhandari et al.; these studies contrasted with the
other three trials. Clearly, the most common reasons for the
decreased level of evidence were the possible risk of bias and
inconsistency.
’ DISCUSSION
In this meta-analysis, we summarized that PTH treatment
in patients with fracture was better than a placebo or no
treatment based on the time for fracture healing, the degree
of fracture pain, and the functional outcomes (Figure 8).
There is great clinical value in healing fractures over a
shorter time, with reductions in pain and with functional
improvements (42). Therefore, these results showed the
effectiveness of PTH in fracture healing. However, previous
studies were inconsistent with the effect of PTH on fracture
healing (25,26). It was shown that PTH is effective in
accelerating fracture healing in the study by Lou et al. (25),
but not in the study by Shi et al. (26). Their studies might
have some limitations, such as including the patients who
received other drugs or different doses (25,26), only includ-
ing the patients with osteoporosis (25), or only including
fracture healing time and functional change (25). Our study
included a total of 524 patients with fractures from 8 RCTs
involving recently published primary studies. We included
more patients and relevant outcomes, and tried to exclude
inappropriate patients.
However, heterogeneity was obvious in this meta-analysis,
so sensitivity analyses and subgroup analyses were per-
formed. We found that the heterogeneity was significantly
lower by exclusion of the trial by Peichl et al. (31). Fractures
at different sites can be healed by different mechanisms (43).
One possible explanation of the heterogeneity was that limb
fracture healing differed from pelvic fracture healing in
response to the anabolic effect of PTH, and we need to study
these two types of fractures separately. Another possible
explanation is that the equivalence of teriparatide and PTH
(1-84) for fracture healing is questionable. Similarly, compar-
ing 4-week treatment (30,37) with over 4-week treatment
(31,33) produced statistically significant differences in terms
of functional improvement following fracture. Although
PTH can improve early callus formation (44), better effects
may be observed with a longer duration of treatment. There-
fore, a uniform duration of treatment is needed to support
clinical decisions.
According to the results from the pooled data, PTH
treatment accelerated fracture healing, which allows patients
to return to normal life sooner and reduces the medical
consumption and chronic morbidity associated with long-
term treatment. Furthermore, PTH can be applied to any type
of fracture, commenced at any time, and applied throughout
the entire healing period. As a result, we suspect that PTH
may be useful in the course of implant fixation and in the
established nonunion fracture. Some studies have started to
explore related issues (45-50), but the number of these studies
is still limited, and most of them are small sample size. The
hypotheses discussed here still need to be addressed by high-
quality RCTs.
It was advantageous that our meta-analysis conformed to
the recommendations of the Cochrane Collaboration (27) and
PRISMA guidelines (28), and the quality of evidence for its
outcomes was evaluated by GRADE system (40). However,
there were still several limitations. First, there were only
eight studies included, and the sample size was relativelyTa
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small. Second, in our study, more than 79% of the fractures
occurred in women, and the average age of participants was
73 years; therefore, we do not know whether the results are
applicable to men or young adults. Third, it was difficult to
guarantee consistent blindness because some RCTs lacked
a placebo or were unclear about the ‘‘random sequence
generation’’ and ‘‘allocation concealment’’.
In conclusion, we determined that the effectiveness and
safety of PTH in fracture healing is reasonably well estab-
lished and credible. At this time, there are not enough studies
in this field, hence we must cautiously interpret these results,
and more high-quality RCTs are needed to verify the
differential effects of PTH on fracture healing in different
populations.
’ ACKNOWLEDGMENTS
This study was funded by research grant No. 81672230 from the National
Natural Science Foundation of China. The authors thank Hui Tang,
Yongsheng Wang and Hu Li for help in preparing the manuscript.
’ AUTHOR CONTRIBUTIONS
Hong H and Deng Z designed the study. Deng Z conducted the study. Li J,
Jiang Q and Song Q were responsible for the data collection. Hong H and
Song T were responsible for data analysis. Hong H was responsible for the
integration of the data analysis and manuscript drafting. Hong H and Liu Y
were responsible for the data interpretation. Hong H, Liu Y, Li J, Jiang Q,
Song T and Deng Z were responsible for revising the manuscript content.
Hong H, Liu Y, Li J, Jiang Q, Song T and Deng Z approved the ﬁnal
version of manuscript.
’ REFERENCES
1. Antonova E, Le TK, Burge R, Mershon J. Tibia shaft fractures: costly
burden of nonunions. BMC Musculoskelet Disord. 2013;14:42, https://
doi.org/10.1186/1471-2474-14-42.
2. Einhorn TA, Gerstenfeld LC. Fracture healing: mechanisms and inter-
ventions. Nat Rev Rheumatol. 2015;11(1):45-54, https://doi.org/10.1038/
nrrheum.2014.164.
3. van Griensven M. Preclinical testing of drug delivery systems to bone.
Adv Drug Deliv Rev. 2015;94:151-64, https://doi.org/10.1016/j.addr.
2015.07.006.
4. Alkhawashki HM. Shock wave therapy of fracture nonunion. Injury.
2015;46(11):2248-52, https://doi.org/10.1016/j.injury.2015.06.035.
5. Wang CJ. Extracorporeal shockwave therapy in musculoskeletal disorders.
J Orthop Surg Res. 2012;7:11, https://doi.org/10.1186/1749-799X-7-11.
6. Mabry TM, Prpa B, Haidukewych GJ, Harmsen WS, Berry DJ. Long-term
results of total hip arthroplasty for femoral neck fracture nonunion. J Bone
Joint Surg Am. 2004;86-A(10):2263-7, https://doi.org/10.2106/00004623-
200410000-00019.
7. Komatsu DE, Warden SJ. The control of fracture healing and its ther-
apeutic targeting: improving upon nature. J Cell Biochem. 2010;109(2):
302-11, https://doi.org/10.1002/jcb.22418.
8. Matsumoto T, Kuroda R, Mifune Y, Kawamoto A, Shoji T, Miwa M, et al.
Circulating endothelial/skeletal progenitor cells for bone regeneration
and healing. Bone. 2008;43(3):434-9, https://doi.org/10.1016/j.bone.2008.
05.001.
9. Hao ZC, Lu J, Wang SZ, Wu H, Zhang YT, Xu SG. Stem cell-derived
exosomes: A promising strategy for fracture healing. Cell Prolif. 2017;
50(5), https://doi.org/10.1111/cpr.12359.
10. Drake MT, Baldassare JJ, McConkey CL, Gonzalez EA, Martin KJ. Para-
thyroid hormone increases the expression of receptors for epidermal
growth factor in UMR 106-01 cells. Endocrinology. 1994;134(4):1733-7,
https://doi.org/10.1210/endo.134.4.8137737.
11. Noordin S, Glowacki J. Parathyroid hormone and its receptor gene poly-
morphisms: implications in osteoporosis and in fracture healing. Rheu-
matol Int. 2016;36(1):1-6, https://doi.org/10.1007/s00296-015-3319-9.
12. Kramer I, Keller H, Leupin O, Kneissel M. Does osteocytic SOST sup-
pression mediate PTH bone anabolism? Trends Endocrinol Metab. 2010;
21(4):237-44, https://doi.org/10.1016/j.tem.2009.12.002.
13. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al.
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on
bone density in men with osteoporosis. J Bone Miner Res. 2003;18(1):9-17,
https://doi.org/10.1359/jbmr.2003.18.1.9.
14. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST,
et al. Parathyroid hormone and teriparatide for the treatment of osteo-
porosis: a review of the evidence and suggested guidelines for its use.
Endocr Rev. 2005;26(5):688-703, https://doi.org/10.1210/er.2004-0006.
15. Rubin MR, Bilezikian JP. Parathyroid hormone as an anabolic skeletal
therapy. Drugs. 2005;65(17):2481-98, https://doi.org/10.2165/00003495-
200565170-00005.
16. Compston J. Recombinant parathyroid hormone in the management of
osteoporosis. Calcif Tissue Int. 2005;77(2):65-71, https://doi.org/10.1007/
s00223-005-0012-0.
17. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY,
et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral
density in postmenopausal women with osteoporosis. N Engl J Med.
2001;344(19):1434-41, https://doi.org/10.1056/NEJM200105103441904.
18. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD.
Parathyroid hormone treatment can reverse corticosteroid-induced osteo-
porosis. Results of a randomized controlled clinical trial. J Clin Invest.
1998;102(8):1627-33, https://doi.org/10.1172/JCI3914.
19. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al.
Randomised controlled study of effect of parathyroid hormone on ver-
tebral-bone mass and fracture incidence among postmenopausal women
on oestrogen with osteoporosis. Lancet. 1997;350(9077):550-5, https://doi.
org/10.1016/S0140-6736(97)02342-8.
20. Rowshan HH, Parham MA, Baur DA, McEntee RD, Cauley E, Carriere
DT, et al. Effect of intermittent systemic administration of recombinant
parathyroid hormone (1-34) on mandibular fracture healing in rats.
J Oral Maxillofac Surg. 2010;68(2):260-7, https://doi.org/10.1016/j.joms.
2009.09.045.
Figure 8 - Comparison of the effectiveness and safety of parathyroid hormone in fracture healing.
9
CLINICS 2019;74:e800 The effect of PTH in fracture healing
Hong H et al.
21. Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH,
et al. Enhancement of experimental fracture-healing by systemic admin-
istration of recombinant human parathyroid hormone (PTH 1-34). J Bone
Joint Surg Am. 2005;87(4):731-41, https://doi.org/10.2106/JBJS.D.02115.
22. Resmini G, Iolascon G. 79-year-old post-menopausal woman with
humerus fracture during teriparatide treatment. Aging Clin Exp Res.
2007;19(Suppl 4):30-1.
23. Knecht TP. Teriparatide and fracture healing in cortical bone. Endocr
Pract. 2004;10(3):293.
24. Rubery PT, Bukata SV. Teriparatide may accelerate healing in delayed
unions of type III odontoid fractures: a report of 3 cases. J Spinal Disord
Tech. 2010;23(2):151-5, https://doi.org/10.1097/BSD.0b013e31819a8b7a.
25. Lou S, Lv H, Wang G, Zhang L, Li M, Li Z, et al. The Effect of Teriparatide
on Fracture Healing of Osteoporotic Patients: A Meta-Analysis of Ran-
domized Controlled Trials. Biomed Res Int. 2016;2016:6040379, https://
doi.org/10.1155/2016/6040379.
26. Shi Z, Zhou H, Pan B, Lu L, Liu J, Kang Y, et al. Effectiveness of Ter-
iparatide on Fracture Healing: A Systematic Review and Meta-Analysis.
PLoS One. 2016;11(12):e0168691, https://doi.org/10.1371/journal.pone.
0168691.
27. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Colla-
boration, 2011. Available from http://handbook.cochrane.org.gsmez-
proxy.utmck.edu
28. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis
JP, et al. The PRISMA statement for reporting systematic reviews and
meta-analyses of studies that evaluate healthcare interventions: expla-
nation and elaboration. BMJ. 2009;339:b2700, https://doi.org/10.1136/
bmj.b2700.
29. Bhandari M, Jin L, See K, Burge R, Gilchrist N, Witvrouw R, et al.
Does Teriparatide Improve Femoral Neck Fracture Healing: Results From
A Randomized Placebo-controlled Trial. Clin Orthop Relat Res. 2016;
474(5):1234-44, https://doi.org/10.1007/s11999-015-4669-z.
30. Kanakaris NK, West RM, Giannoudis PV. Enhancement of hip
fracture healing in the elderly: Evidence deriving from a pilot random-
ized trial. Injury. 2015;46(8):1425-8, https://doi.org/10.1016/j.injury.2015.
06.033.
31. Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84
accelerates fracture-healing in pubic bones of elderly osteoporotic women.
J Bone Joint Surg Am. 2011;93(17):1583-7, https://doi.org/10.2106/JBJS.
J.01379.
32. Almirol EA, Chi LY, Khurana B, Hurwitz S, Bluman EM, Chiodo C, et al.
Short-term effects of teriparatide versus placebo on bone biomarkers,
structure, and fracture healing in women with lower-extremity stress
fractures: A pilot study. J Clin Transl Endocrinol. 2016;5:7-14, https://doi.
org/10.1016/j.jcte.2016.05.004.
33. Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, et al.
Teriparatide for acceleration of fracture repair in humans: a prospective,
randomized, double-blind study of 102 postmenopausal women with
distal radial fractures. J Bone Miner Res. 2010;25(2):404-14, https://doi.
org/10.1359/jbmr.090731.
34. Huang TW, Chuang PY, Lin SJ, Lee CY, Huang KC, Shih HN, et al.
Teriparatide Improves Fracture Healing and Early Functional Recovery
in Treatment of Osteoporotic Intertrochanteric Fractures. Medicine. 2016;
95(19):e3626, https://doi.org/10.1097/MD.0000000000003626.
35. Zura R, Xu ZJ, Della Rocca GJ, Mehta S, Steen RG. When Is a Fracture Not
‘‘Fresh’’? Aligning Reimbursement With Patient Outcome After Treatment
With Low-Intensity Pulsed Ultrasound. J Orthop Trauma. 2017;31(5):
248-51, https://doi.org/10.1097/BOT.0000000000000778.
36. Chesser TJ, Fox R, Harding K, Halliday R, Barnfield S, Willett K, et al. The
administration of intermittent parathyroid hormone affects functional
recovery from trochanteric fractured neck of femur: a randomised pro-
spective mixed method pilot study. Bone Joint J. 2016;98-B(6):840-5,
https://doi.org/10.1302/0301-620X.98B6.36794.
37. Johansson T. PTH 1-34 (teriparatide) may not improve healing in prox-
imal humerus fractures. A randomized, controlled study of 40 patients.
Acta Orthop. 2016;87(1):79-82, https://doi.org/10.3109/17453674.2015.
1073050.
38. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency
in meta-analyses. BMJ. 2003;327(7414):557-60, https://doi.org/10.1136/
bmj.327.7414.557.
39. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control
Clin Trials. 1986;7(3):177-88, https://doi.org/10.1016/0197-2456(86)
90046-2.
40. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al.
Grading quality of evidence and strength of recommendations. BMJ. 2004;
328(7454):1490, https://doi.org/10.1136/bmj.328.7454.1490.
41. Campbell EJ, Campbell GM, Hanley DA. The effect of parathyroid hor-
mone and teriparatide on fracture healing. Expert Opin Biol Ther. 2015;
15(1):119-29, https://doi.org/10.1517/14712598.2015.977249.
42. Morshed S, Corrales L, Genant H, Miclau T 3rd. Outcome assessment in
clinical trials of fracture-healing. J Bone Joint Surg Am. 2008;90(Suppl 1):
62-7, https://doi.org/10.2106/JBJS.G.01556.
43. Sandberg OH, Aspenberg P. Inter-trabecular bone formation: a specific
mechanism for healing of cancellous bone. Acta Orthop. 2016;87(5):
459-65, https://doi.org/10.1080/17453674.2016.1205172.
44. Aspenberg P, Johansson T. Teriparatide improves early callus formation in
distal radial fractures. Acta Orthop. 2010;81(2):234-6, https://doi.org/
10.3109/17453671003761946.
45. Bashutski JD, Eber RM, Kinney JS, Benavides E, Maitra S, Braun TM, et al.
Teriparatide and osseous regeneration in the oral cavity. N Engl J Med.
2010;363(25):2396-405, https://doi.org/10.1056/NEJMoa1005361.
46. Kobayashi N, Inaba Y, Uchiyama M, Ike H, Kubota S, Saito T. Teriparatide
Versus Alendronate for the Preservation of Bone Mineral Density After
Total Hip Arthroplasty - A randomized Controlled Trial. J Arthroplasty.
2016;31(1):333-8, https://doi.org/10.1016/j.arth.2015.07.017.
47. Matsumoto T, Ando M, Sasaki S. Effective treatment of delayed union of
a lumbar vertebral fracture with daily administration of teriparatide in
a patient with diffuse idiopathic skeletal hyperostosis. Eur Spine J. 2015;
24(Suppl 4):S573-6, https://doi.org/10.1007/s00586-014-3733-9.
48. Lee YK, Ha YC, Koo KH. Teriparatide, a nonsurgical solution for femoral
nonunion? A report of three cases. Osteoporos Int. 2012;23(12):2897-900,
https://doi.org/10.1007/s00198-012-2172-x.
49. Chintamaneni S, Finzel K, Gruber BL. Successful treatment of sternal
fracture nonunion with teriparatide. Osteoporos Int. 2010;21(6):1059-63,
https://doi.org/10.1007/s00198-009-1061-4.
50. Tamai K, Takamatsu K, Kazuki K. Successful treatment of nonunion
with teriparatide after failed ankle arthrodesis for Charcot arthropathy.
Osteoporos Int. 2013;24(10):2729-32, https://doi.org/10.1007/s00198-013-
2367-9.
10
The effect of PTH in fracture healing
Hong H et al.
CLINICS 2019;74:e800
